Yoshimi Shimizu

Years Active: 2020-2022
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Yuichiro Yamamoto, Yoshio Nakano, Mana Murae, Yoshimi Shimizu, Shota Sakai, Motohiko Ogawa, Tomoharu Mizukami, Tetsuya Inoue, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Masayoshi Fukasawa, Satoru Miyazaki, Kohji Noguchi
Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic Acid. International journal of molecular sciences 24 (1) (2022)
Yuichiro Yamamoto, Yoshio Nakano, Mana Murae, Yoshimi Shimizu, Shota Sakai, Motohiko Ogawa, Tomoharu Mizukami, Tetsuya Inoue, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Masayoshi Fukasawa, Satoru Miyazaki, Kohji Noguchi
Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic Acid. International journal of molecular sciences 24 (1) (2022)
Yuichiro Yamamoto, Yoshio Nakano, Mana Murae, Yoshimi Shimizu, Shota Sakai, Motohiko Ogawa, Tomoharu Mizukami, Tetsuya Inoue, Taishi Onodera, Yoshimasa Takahashi, Takaji Wakita, Masayoshi Fukasawa, Satoru Miyazaki, Kohji Noguchi
Direct Inhibition of SARS-CoV-2 Spike Protein by Peracetic Acid. International journal of molecular sciences 24 (1) (2022)
Yoshimi Shimizu, Takehiro Shinoda, Yoshitaka Shirasago, Masuo Kondoh, Naoko Shinya, Kentaro Hanada, Kiyohito Yagi, Tetsuro Suzuki, Takaji Wakita, Tomomi Kimura-Someya, Mikako Shirouzu, Masayoshi Fukasawa
Occludin-binding single-chain variable fragment and antigen-binding fragment antibodies prevent hepatitis C virus infection. FEBS letters 595 (2) (2020)

Yoshimi Shimizu.css-eqlu8i{font-size:small;padding-left:4px;}